Cholangiocarcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We engineer human liver organoids to combine four common cholangiocarcinoma mutations (TP53, PTEN, SMAD4, and NF1).
|
31130514 |
2019 |
Cholangiocarcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast, mutations of phosphatase and tensin homolog (PTEN) and tumor protein 53 (TP53) appeared to be higher in HGG tumors in CC patients than in their AA counterparts.
|
29599344 |
2018 |
Cholangiocarcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Only a few studies have evaluated the clinicopathological significance of the p53 protein expression and s-p53-Abs level in patients with cholangiocarcinoma.
|
28508195 |
2017 |
Cholangiocarcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Besides, the expression of CXCL7 was significantly associated with the Ki67 expression, but not associated with CA199, AFP, or P53 expression in cholangiocarcinoma.
|
27959418 |
2017 |
Cholangiocarcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that p53 is important for the activation of autophagy in nutrient-deprived cholangiocarcinoma cells, and thus contributes to cell survival and chemoresistance.
|
28789429 |
2017 |
Cholangiocarcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here we characterize Notch in human-resected CC, a toxin-driven model in rats, and a transgenic mouse model in which p53 deletion is targeted to biliary epithelia and CC induced using the hepatocarcinogen thioacetamide.
|
27791012 |
2016 |
Cholangiocarcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.
|
24204826 |
2013 |
Cholangiocarcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Exome sequencing of liver fluke-associated cholangiocarcinoma.
|
22561520 |
2012 |
Cholangiocarcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma.
|
22230750 |
2012 |
Cholangiocarcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
|
20422343 |
2010 |
Cholangiocarcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Of the molecular markers which have been investigated to date, p53 mutation, cyclins, proliferation indices, mucins, CA19-9, CRP and aneuploidy appear to hold significant potential as predictors of outcome in CC.
|
18938071 |
2009 |
Cholangiocarcinoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Expression of P53 protein could not act as an independent index to estimate the prognosis of cholangiocarcinoma.
|
16937443 |
2006 |
Cholangiocarcinoma
|
0.600 |
Biomarker
|
disease |
CTD_mouse |
Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
|
16818635 |
2006 |
Cholangiocarcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of P53 protein could not act as an independent index to estimate the prognosis of cholangiocarcinoma.
|
16937443 |
2006 |
Cholangiocarcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Five non-silent p53 mutations were found, including three new frameshift mutations and two new intron mutations which have not previously been reported in cholangiocarcinoma.
|
16596244 |
2006 |
Cholangiocarcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The findings of previous p53 studies and their relevance in human cholangiocarcinoma are summarised.
|
15998419 |
2005 |
Cholangiocarcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A series of nine CC, 15 HCC-CC and three separated HCC and CC lesions ('collision tumors') were screened for loss of heterozygosity (LOH) using 400 microsatellite markers and for p53 and beta-catenin mutations.
|
15288479 |
2004 |
Cholangiocarcinoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.
|
12829999 |
2003 |
Cholangiocarcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accumulation of multiple genetic alterations are involved in the tumorigenesis of CC, of which genetic alterations of APC and DCC occur at a relatively early stage, and of OGG1 and p53 occur at a relatively late stage during development of CC.
|
11260864 |
2001 |
Cholangiocarcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ki-67, bcl-2, p53 or DNA fragmentation were not significantly different in nontumorous liver tissue from patients with and without CC.
|
11168786 |
2001 |
Cholangiocarcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We investigated the occurrence of K-ras codon 12 and 13 mutations, p53 protein accumulation, and Ki-67 expression in tumor tissue from PSC patients (n=33) who had developed cholangiocarcinoma, using bile duct specimens exised at liver transplantation of PSC patients without cholangiocarcinoma (n=15) as controls
|
10735605 |
2000 |
Cholangiocarcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The presence of TP53 mutations or upregulation of MDM2 gene expression in 9 of the 13 cholangiocarcinomas strongly supports that the impairment of the p53 pathway is an important and specific step in cholangiocarcinoma pathogenesis.
|
10718212 |
2000 |
Cholangiocarcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The incidence of p53 mutations was 33.3% in CC and 42.9% in GBC. p53 protein overexpression was observed in 60% CC biopsy specimens.
|
10227722 |
1999 |
Cholangiocarcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We failed to establish p73 or p53 as independent prognostic factors in cholangiocellular carcinoma of the liver.
|
10362118 |
1999 |
Cholangiocarcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Significantly more cholangiocarcinomas from the West Virginia group were p53-immunohistochemical-positive than from the non-West Virginia group (67% vs. 20%; p < 0.05). p53 mutations did not differ in the 2 groups in respect to site or specific type.
|
9833761 |
1998 |